We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) closed at $75.07 in the latest trading session, marking a +0.15% move from the prior day. This change lagged the S&P 500's 1.84% gain on the day. At the same time, the Dow added 1.33%, and the tech-heavy Nasdaq gained 0.53%.
Coming into today, shares of the biopharmaceutical company had lost 1.77% in the past month. In that same time, the Medical sector lost 1.18%, while the S&P 500 lost 0.5%.
Wall Street will be looking for positivity from Bristol Myers Squibb as it approaches its next earnings report date. The company is expected to report EPS of $1.91, down 1.04% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.52 billion, down 1.55% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $7.61 per share and revenue of $46.33 billion. These totals would mark changes of +1.33% and -0.12%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Bristol Myers Squibb is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Bristol Myers Squibb's current valuation metrics, including its Forward P/E ratio of 9.85. This valuation marks a discount compared to its industry's average Forward P/E of 21.41.
Investors should also note that BMY has a PEG ratio of 1.58 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.16 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 104, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
Bristol Myers Squibb (BMY - Free Report) closed at $75.07 in the latest trading session, marking a +0.15% move from the prior day. This change lagged the S&P 500's 1.84% gain on the day. At the same time, the Dow added 1.33%, and the tech-heavy Nasdaq gained 0.53%.
Coming into today, shares of the biopharmaceutical company had lost 1.77% in the past month. In that same time, the Medical sector lost 1.18%, while the S&P 500 lost 0.5%.
Wall Street will be looking for positivity from Bristol Myers Squibb as it approaches its next earnings report date. The company is expected to report EPS of $1.91, down 1.04% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.52 billion, down 1.55% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $7.61 per share and revenue of $46.33 billion. These totals would mark changes of +1.33% and -0.12%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Bristol Myers Squibb is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Bristol Myers Squibb's current valuation metrics, including its Forward P/E ratio of 9.85. This valuation marks a discount compared to its industry's average Forward P/E of 21.41.
Investors should also note that BMY has a PEG ratio of 1.58 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.16 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 104, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.